Tiziana Life Sciences’ (NASDAQ:TLSA) Chairman of Scientific Advisory Board, Dr. Howard Weiner, has received
a competitive research grant from the National Institutes of Health
(NIH) to investigate nasal anti-CD3 for the treatment of Alzheimer’s
disease.
Encouraging results of nasal anti-CD3 in animal
models provides basis to move forward with clinical development of
nasally administered Foralumab, the only entirely human anti-CD3
monoclonal antibody, for the potential treatment of Alzheimer’s and
other neurodegerative diseases in humans.
To date the Company has successfully completed two
phase 1 trials and intends to initiate two phase 2 trials with nasally
and orally administered Foralumab shortly for treatment of progressive
multiple sclerosis and Crohn’s disease, respectively.
https://seekingalpha.com/news/3580323-tiziana-nabs-nih-grant-to-investigate-nasal-anti-cd3-in-alzheimer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.